Stockreport

Mural Oncology Highlights Pipeline Progress and Anticipated 2025 Catalysts

Mural Oncology plc - Ordinary Shares  (MURA) 
PDF Readouts for two late-stage, potentially registrational trials of nemvaleukin alfa expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 fo [Read more]